University of California, San Francisco

Med Schools Fear Board Exam Changes Could Impede Diversity and MD Preparedness

Retrieved on: 
Wednesday, August 23, 2023
Cognition, Medical school, USMLE, University, Interview, Workplace, Anxiety, Physician, University of California, San Francisco, Duke University School of Medicine, University of California, Kate Campbell, Student, National Resident Matching Program, NRMP, Patient, UCSF, Columbia University Vagelos College of Physicians and Surgeons, School, USMLE Step 1, DEI, UCLA, Mental health, Nursing, Medicine, Surgeon

MOORESVILLE, N.C., Aug. 23, 2023 /PRNewswire-PRWeb/ -- The United States Medical Licensing Examination® (USMLE®) is undeniably one of toughest and most competitive tests on the planet. Developed to assess medical students' preparedness for the workplace, passing the three-step test is required for anyone wishing to practice medicine in the U.S.

Key Points: 
  • Until recently, USMLE Step 1 was based on a three-digit score, from 1 to 300.
  • The higher the score, the more likely a student would match into their desired residency specialty and program.
  • More than half of respondents indicated that 5% or more of their medical students undergo formal remediation or delays each year.
  • Vendors, educators, and policymakers must work together to ensure positive outcomes for all medical students and ultimately the patients they treat."

ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study

Retrieved on: 
Wednesday, August 23, 2023
University, Safety, University of California, San Francisco, ADHD, Medicine, CNS, Arbutus Biopharma, Plant, UCSF, Medical Center, Ophthalmology, Phase, Medical device, Polaris, Patient

(NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that 60 subjects had been enrolled and 53 had completed the eight-week study for the Company's ADHD Phase IIb clinical study.

Key Points: 
  • (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that 60 subjects had been enrolled and 53 had completed the eight-week study for the Company's ADHD Phase IIb clinical study.
  • The study entitled "A Phase IIb Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients with Adult Attention-Deficit/Hyperactivity Disorder" is a randomized, double-blind, placebo-controlled study involving a total of approximately 100 patients in the United States and Taiwan.
  • The Phase IIb clinical study continues the Phase IIa clinical study of ABV-1505.
  • "At all of our sites, the enrollment of subjects participating in our ADHD Phase IIb study is going as planned," said ABVC BioPharma Chief Executive Officer Uttam Patil, Ph.

Foundery Launches Inaugural Biotech Venture Creation Fund to Accelerate the Development of Novel Immunotherapies

Retrieved on: 
Tuesday, August 22, 2023
San Francisco, Partnership, Drug development, University, Intellectual property, Horizon Therapeutics, Mount Parnassus, Biotechnology, University of California, San Francisco, Like a Boss (film), Saṃsāra, MBA, Partner (business rank), Research, Inflammation, Immunotherapy, Autoimmunity, Translation, Redpoint Ventures, Investigational New Drug, UCSF, SAN, Growth, IND, Pharmaceutical industry, Cryptocurrency, The Foundery

“Foundery is pleased to launch this new fund with the support of our limited partners who share in our belief that by fostering integrated early-stage drug development collaborations with university investigators, we can accelerate the cost-effective creation of novel immunotherapies that hold the potential to transform lives,” said Dr. Krummel.

Key Points: 
  • “Foundery is pleased to launch this new fund with the support of our limited partners who share in our belief that by fostering integrated early-stage drug development collaborations with university investigators, we can accelerate the cost-effective creation of novel immunotherapies that hold the potential to transform lives,” said Dr. Krummel.
  • Foundery anticipates initiating business development activities for its pre-IND drug development candidates as early as the second half of 2024.
  • Limited Partners in Foundery Fund I include an established family office, a public research university endowment, and growth and impact-oriented high-net worth individuals.
  • Foundery’s advisors offer expertise and external review across venture investing, operations, M&A and business development activities.

NASA's SpaceX Crew-7 Astronauts to Embark on Six-Month Science Expedition, Supporting an Array of R&D on the Space Station

Retrieved on: 
Monday, August 21, 2023
ISS National Lab, Commercial Crew Program, Life, SPACE, Administration, Redwire, Commercial Resupply Services, Bangladesh Technical Education Board, DARPA, NASA, Patient, University, Scientific research on the International Space Station, ISS, San Francisco, Endurance, Ray (optics), Reliability, Therapy, NSF, European Space Agency, International Space Station, Research, United States Naval Research Laboratory, Survival, Bacteria, SpaceX Crew-7, JAXA, Semiconductor, Biotechnology, Spacecraft, Liver regeneration, Cell, MassChallenge, Human body, Boeing, ESA, University of California, San Francisco, EDT, Kennedy Space Center, LEO, CASIS, Exploration, Communications satellite, Pharmaceutical industry, SpaceX, Science

While onboard the space station, the Crew-7 astronauts, who will be part of Expeditions 69 and 70, will perform a variety of investigations sponsored by the ISS National Laboratory.

Key Points: 
  • While onboard the space station, the Crew-7 astronauts, who will be part of Expeditions 69 and 70, will perform a variety of investigations sponsored by the ISS National Laboratory.
  • In the coming months, a variety of visiting vehicles will launch to the space station.
  • These endeavors will bring value to humanity through space-based inquiry, further our ability to explore, and enable a robust LEO market.
  • The U.S. National Science Foundation (NSF) will support multiple investigations in the life and physical sciences over the course of Expedition 70.

AI Therapeutics Announces Investigator Initiated Phase 2 Trial at UCSF to Study LAM-001 in Patients With Bronchiolitis Obliterans Syndrome (BOS) Post-Lung Transplant

Retrieved on: 
Friday, August 18, 2023
Bronchiolitis, Therapy, BOS, Survival, Pathology, University of California, San Francisco, Quality of life, Inflammation, Sirolimus, Transplant, BAL, Regeneration, MD, UCSF, Patient, Blood, Epithelium, Principal, Rare, Death, FEV1, Respiratory failure, Safety, Dentistry

BOS remains the leading cause of death after transplantation and affects approximately 50% of all lung transplant recipients by 5 years.

Key Points: 
  • BOS remains the leading cause of death after transplantation and affects approximately 50% of all lung transplant recipients by 5 years.
  • “BOS is a major complication in lung transplant patients for which there are no approved therapies.
  • BOS pathology is driven by inflammation of the small airways, fibroproliferation and abnormal regeneration of the epithelium.
  • “While retrospective analyses have shown that oral sirolimus can improve survival in BOS patients, systemic toxicities have limited its widespread adoption.

Silo Pharma Engages Clarivate for Intellectual Property and Patent Management

Retrieved on: 
Thursday, August 10, 2023
Columbia University, San Francisco, Patent, Intellectual property, Clarivate, Drug development, Psychopathology, Therapy, Central nervous system, University, Anxiety, University of California, San Francisco, Composition, Research, Biomarker, IP, CNS, History of the University of Maryland, College Park, Pain, Dementia, Investigational New Drug, Acquisition, FDA, United States patent law, Information services, SILO, IND, Alzheimer's disease, PTSD, Peptide, Pharmaceutical industry

ENGLEWOOD CLIFFS, NJ, Aug. 10, 2023 (GLOBE NEWSWIRE) --  Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, announced today that it has retained the services of Clarivate™, a leading global provider of information services including IP lifecycle management solutions. Under terms of the agreement, Clarivate will manage, maintain, and track the Company’s intellectual property assets and technology rights, and serve as an advisor for strategic IP and patent expansion in support of pipeline development.

Key Points: 
  • Under terms of the agreement, Clarivate will manage, maintain, and track the Company’s intellectual property assets and technology rights, and serve as an advisor for strategic IP and patent expansion in support of pipeline development.
  • Silo Pharma engages in the acquisition, licensing, and development of intellectual property and technology rights from leading universities and researchers, including the use of psychedelic drugs.
  • “Our new agreement with Clarivate gives us the opportunity to step up our intellectual property and patent expansion efforts and reinforce protection for our novel assets under development,” said Eric Weisblum, Chief Executive Officer of Silo Pharma.
  • In 2023, year-to-date, Silo Pharma has been awarded 3 new patents and one patent extension:
    U.S. Patent 16/825,371, covering SPU-21 as a method of selectively targeting inflamed synovial tissue.

ABVC Corporate Update and CEO's Letter to Shareholders

Retrieved on: 
Monday, August 7, 2023
West Pharmaceutical Services, GMP, Cayman, Good manufacturing practice, SIV, TID, Attention deficit hyperactivity disorder, Investigational New Drug, Acquisition, Patient, Neurology, News, San Francisco, Letter, University, UCSF, Ophthalmology, Growth, TGA, Shoe, FDA, IND, Pancreatic cancer, ADHD, Cancer, Attention deficit hyperactivity disorder predominantly inattentive, Taiwan Stock Exchange, Dietary supplement, MDD, Syndrome, Triple-negative breast cancer, Partnership, University of California, San Francisco, MDS, CDMO, DSM-IV codes, BID, ANDA, US FDA, Pharmaceutical industry, Qiu Zhonghui, Polaris

FREMONT, CA, Aug. 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, today published a Corporate Update and Letter to Shareholders from recently appointed Chief Executive Officer, Dr. Uttam Patil.

Key Points: 
  • FREMONT, CA, Aug. 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, today published a Corporate Update and Letter to Shareholders from recently appointed Chief Executive Officer, Dr. Uttam Patil.
  • As we move into the second half of 2023, I am delighted to speak about ABVC's recent developments and plans.
  • ABVC and BioFirst Corporation expect to complete the facility's construction in Hsinchu Biomedical Science Park, Taiwan, in 2024.
  • The product is ready for an End-of-Phase II meeting with the FDA to finalize the protocol for Phase III trials.

Ovarian Cancer: New Biological Markers Found That May Predict Which Patients Won't Respond to Chemotherapy

Retrieved on: 
Thursday, August 3, 2023
San Francisco, Doctor of Public Health, Mayo Clinic, University, University of Minnesota, Icahn School of Medicine at Mount Sinai, Neoplasm, University of Washington, Cohort (statistics), New York University Grossman School of Medicine, University of California, San Francisco, Baylor University, National Cancer Institute, Toxicity, MBA, Research, Mount Sinai, Doctor of Philosophy, University of Miami, Proteomics, MS, Amanda Paulovich, MD Anderson Cancer Center, University of Michigan School of Kinesiology, Death, Protein, Michigan Medicine, Patient, James D. Watson Institute of Genome Sciences, Baylor College of Medicine, University of Arkansas, Mortality, Trial of the century, Fred Hutchinson Cancer Research Center, Ovarian cancer, Dana–Farber Cancer Institute, Vaccine, Pharmaceutical industry, Medical imaging, Management, Genetics, MD, Cell, Medicine

NEW YORK, Aug. 3, 2023 /PRNewswire-PRWeb/ -- Using a novel proteogenomic strategy and a variety of machine learning tools, investigators from the Icahn School of Medicine at Mount Sinai and colleagues have identified a 64-protein signature that may predict a subset of ovarian cancer patients who are unlikely to respond to chemotherapy.

Key Points: 
  • The multicenter study, published online August 3 in Cell, reports on a pioneering analysis of chemo-refractoriness in high-grade serous ovarian cancer (HGSOC).
  • The multicenter study, published online August 3 in Cell [DOI#: 10.1016/j.cell.2023.07.004], reports on a pioneering analysis of chemo-refractoriness in high-grade serous ovarian cancer (HGSOC).
  • Currently, there's no way to distinguish refractory cases (who never respond to chemotherapy), leading some patients to unnecessarily experience the adverse effects of platinum-based chemotherapy without the benefits.
  • The investigators studied 242 tumors samples collected from HGSOC patients comprising both chemo-refractory and chemo-responsive individuals before they received chemotherapy.

Movano Health Achieves Major Milestone with First FDA Filing for Evie Ring's Pulse Oximeter

Retrieved on: 
Thursday, August 3, 2023
San Francisco, Partnership, University, University of California, San Francisco, Sleep, Woman, Pulse, BPM, Oxygen saturation (medicine), UCSF, Heart rate, Health, FDA, Skin temperature, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Conditional sentence, Medical device, Evie

PLEASANTON, Calif. , Aug. 3, 2023 /PRNewswire/ -- Today, Movano Health (Nasdaq: MOVE), a purpose-driven healthcare solutions company at the intersection of medical and consumer devices and makers of the Evie Ring, announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the Company's first commercial product, the Evie Ring. The submission has passed the first milestone of the review process, an initial review for completeness, and is now under full review by the FDA.

Key Points: 
  • The submission has passed the first milestone of the review process, an initial review for completeness, and is now under full review by the FDA.
  • One of the most critical components of the FDA submission is the ring's clinical performance.
  • In Q4 2022, Movano Health completed a successful pivotal hypoxia trial with the University of California, San Francisco (UCSF) to assess the accuracy of Evie's blood oxygen saturation (SpO2).
  • This first submission to the FDA marks a momentous milestone for our team and sets the stage for future FDA filings," said John Mastrototaro, CEO of Movano Health.

Advances in Big Data for Precision Medicine, Novel Technologies to Determine a Pathogen's Susceptibility to Antibiotics, the Microbiome's Impact on Childhood Undernutrition, and More Draw Nearly 20,000 Attendees to 2023 AACC Annual Scientific Meeting

Retrieved on: 
Thursday, July 27, 2023
Infection, Emory University School of Medicine, Disruptive innovation, Medical laboratory, University, Therapy, AACC, Diagnosis, Big data, Gastrointestinal tract, University of California, San Francisco, Boston Medical Center, Health equity, Single-cell analysis, Woman, Cell, Mass spectrometry, Collection, Patient, Medicine, Hematology, Sickle cell disease, Artificial intelligence, Knowledge, Health, Automation, Disease, Medical device, Pharmaceutical industry

The meeting's 250-plus sessions affirmed that laboratory medicine professionals are essential to patient care.

Key Points: 
  • The meeting's 250-plus sessions affirmed that laboratory medicine professionals are essential to patient care.
  • More attendees are expected today, the last day of the meeting.
  • In addition, this year's Clinical Lab Expo boasted 910 exhibitors, a testament to the health and vibrancy of the field.
  • As part of ADLM's Disruptive Technology Award competition, biotech innovators presented novel technologies that could help more patients get accurate diagnoses.